When a donor heart becomes available, the standard way to move it has not changed in decades. Surgeons flush it with a cold solution, seal it in a plastic bag, set it on ice and carry it in a cooler.1
On ice, the heart is not beating and gets no oxygen. Damage builds with every hour. Doctors cannot test whether it still works, and cannot improve its condition on the way.1
TransMedics puts the cost bluntly: under cold storage, it says, most lungs and hearts donated after brain death go unused, and almost none donated after circulatory death are used.1
Meanwhile, the federal government’s count:2
- 109,817 people are on the national transplant waiting list.
- 12 people die each day waiting for a transplant.
- A new person is added every 7 minutes.
A Heart That Beats Outside the Body
TransMedics’ Organ Care System (OCS) replaces the cooler. It pumps warm, oxygenated, nutrient-rich blood through the donor organ, so that on the way to the patient, in the company’s words, “the lung is breathing, the heart is beating and the liver is producing bile.”1
The FDA has granted premarket approval to OCS Heart, OCS Lung and OCS Liver, for organs from both brain-death and circulatory-death donors. TransMedics says the OCS is the only FDA-approved portable warm perfusion platform for more than one organ.1
And it does not just sell a machine. Through its National OCS Program, TransMedics sends its own surgeons and specialists to the donor hospital and flies the organ to the transplant center on its own fleet: 22 aircraft, 140 dedicated pilots, 20 clinical hubs, more than 50 procurement surgeons and more than 250 clinical specialists, according to the company.3 Substantially all of its U.S. customers now use the program.1

A Real Business, Already at Scale
Plenty of medical-device stories are still a prototype and a promise. TransMedics is selling, at scale, and generating cash:1, 3, 4
- Revenue rose from about $94 million in 2022 to $605.5 million in 2025, a compound annual growth rate of 86%, by the company’s count.
- TransMedics expects $737 million to $757 million in 2026, growth of about 22% to 25%. It reiterated that range on September 10.5
- Second-quarter 2026 revenue was a record $189.9 million, up 21%, with service revenue up 29%.
- Operating activities generated $192.8 million in cash in 2025, against $59.3 million spent on property and equipment.1
Much of that revenue repeats: each transplant with the OCS uses a single-use, organ-specific disposable set, alongside the program’s procurement and flight services.1
In 2026 the company is putting that cash to work. Operating expenses rose to $89.5 million in the second quarter, which TransMedics attributes to planned investment in OCS Kidney, its next-generation OCS platform and new clinical trials. It still earned $23.7 million from operations in the quarter.4
The Long Runway
TransMedics has laid out four growth programs, each aimed at organs the OCS does not reach today. By the company’s estimates:3
- More hearts and lungs. About 2,200 U.S. donor hearts and 3,200 U.S. lung transplants in 2025 were not reached by the OCS. Two trials, ENHANCE Heart and DENOVO Lung, are designed to widen its use.
- Kidneys, the largest transplant category. About 21,000 U.S. kidney transplants a year are addressable, and about 9,100 donated kidneys are discarded each year. TransMedics estimates the kidney waiting list costs Medicare about $10.3 billion a year. OCS Kidney is in development and is the first organ planned for its next-generation platform.
- Europe. About 37,500 organ transplants were performed there in 2025. On July 1 TransMedics completed an investment in PAD Aviation, a German private aviation operator, as a first step toward a European organ-flight network.4
- A next-generation OCS. A cloud-connected, automated platform the company says is designed for scale and operating leverage.
TransMedics is also preparing an entry into Latin America, led by its former finance chief,5 and has signed a 16-year lease on a new headquarters in Somerville, Massachusetts, which it expects to occupy by January 1, 2028.6

The Track Record, and the Opening
TransMedics shares have risen with the business. From October 2021 to October 12, 2026, the stock’s price rose about 189%. Over the same period the iShares U.S. Medical Devices ETF (IHI) fell about 17%, and the S&P 500 (SPY) rose about 73%.8
Over the past year, as TransMedics poured cash into kidneys, Europe and its next-generation machine, the shares pulled back about 34%, from $117.63 to $78.17.8 The cost of those programs is already in today’s margins. The revenue they are meant to produce is not yet in the numbers.
That gap is what long-term investors may want to study. This company has already taken its business from about $94 million to more than $600 million in annual revenue in three years.3, 1 Now it is aiming the same platform at the largest transplant category, kidneys, and at Europe, where about 37,500 organ transplants were performed in 2025, by the company’s count.3 Any one of those programs would build on a business that already makes money; several could change its size.
Investors with a five-to-ten-year horizon may want to put TMDX on their watchlist and do their own research on whether it fits their portfolio.

Funded From Strength
TransMedics is paying for that push from a strong position. At June 30, 2026, it held $472.7 million in cash.4 Its main debt, $460 million of convertible notes due June 2028, was sold to institutional investors at an interest rate of just 1.50% a year, and converts into shares at about $94.00 each.7 It also has a $60 million term loan.7 The company has never paid a dividend and does not expect to in the foreseeable future, keeping its cash for growth.1
The Bottom Line
More than 100,000 Americans are waiting for an organ, and a dozen die each day. Cold storage on ice, TransMedics says, is still the standard of care for moving the organs that could help them.
TransMedics says it makes the only FDA-approved portable warm-perfusion system for more than one organ, and it has built a national surgical and flight network to deliver it. Revenue has grown more than sixfold in three years, the business generates cash, and the company is now spending to take the OCS into kidneys, Europe and a new generation of machines.
For investors who think in five- and ten-year terms, the question is how much of that runway TransMedics can turn into revenue, and the work to answer it starts with the company’s filings.
Key risks
- Concentration. TransMedics depends on the OCS and its National OCS Program, and a limited number of customers account for a significant portion of revenue.1
- Clinical and regulatory risk. The ENHANCE and DENOVO trials may not show superiority over cold storage, and OCS Kidney may never be approved.1
- Spending and margins. Operating margin fell to 12.5% in Q2 2026 from 23.2% a year earlier, and net income fell to $14.7 million from $34.9 million, as spending rose.4
- Debt and dilution. The $460 million of notes must be repaid or converted by June 2028; conversion or new financing could dilute shareholders.1, 7
- Volatility. The shares fell about 34% over the past year. Past performance does not predict future results.8
- Operations. The program relies on aircraft, pilots and FAA licenses, on single-source suppliers, and faces competition from cold storage and other perfusion makers. TransMedics has also reported a material weakness in its internal control over financial reporting.1, 7
Forward-looking statements. TransMedics' 2026 revenue guidance, its estimates of untapped heart, lung, kidney and European transplant volumes and kidney waiting-list costs, its trial, product, Latin America and headquarters plans are company statements about future events or company estimates. None of them may happen, and actual results may differ materially. Share-price figures are price changes only, exclude dividends and are not a prediction. Richport has not independently verified the company's statements and will not update them. Read TransMedics' SEC filings, including the risk factors in its Form 10-K and Form 10-Q, for a full discussion.

References
- TransMedics Group Form 10-K for the year ended December 31, 2025 — SEC EDGAR (February 24, 2026)
- Organ Donation Statistics — Health Resources and Services Administration (HRSA), using OPTN data (Last reviewed August 2026)
- TransMedics presentation, Baird 2026 Global Healthcare Conference — Company source: TransMedics Group (September 15, 2026)
- TransMedics second quarter 2026 results (Form 8-K, Ex. 99.1) — SEC EDGAR (August 4, 2026)
- TransMedics Form 8-K: CFO appointment; 2026 outlook reiterated (Ex. 99.1) — SEC EDGAR (September 10, 2026)
- TransMedics Form 8-K: Somerville headquarters lease — SEC EDGAR (January 12, 2026)
- TransMedics Form 10-Q for the quarter ended June 30, 2026 — SEC EDGAR (August 4, 2026)
- TMDX, IHI and SPY historical prices — Nasdaq.com (Closing prices through October 12, 2026)
lobal Securities News